Migraine Survey in Gulf Region - Trial NCT06237062
Access comprehensive clinical trial information for NCT06237062 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Migraine. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Apr 30, 2024
Jan 30, 2025
Primary Outcome
Mean score in the Treatment Satisfaction Questionnaire for Erenumab (TSQM) overall satisfaction scale score version 1.4
Summary
The objective of this study is to evaluate the effect of erenumab on medication-specific
 treatment satisfaction in patients newly started on erenumab over 12 weeks
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06237062
Non-Device Trial